Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent

US9101668B2 · kind B2 · utility

Assignees

• PURDUE PHARMA L.P. · US
• PURDUE PHARMACEUTICALS L.P. · US
• The P.F. Laboratories, Inc. · US

Inventors

• Benjamin Oshlack · Boca Raton, US
• Curtis Wright · Gloucester, US
• Christopher Breder · Bethesda, US

Key dates

• Filing date: Aug 1, 2013
• Grant date: Aug 11, 2015
• Expiry date: Aug 1, 2033

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P25/36
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic, an opioid antagonist and one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid.